At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 623 enrolled
Drug / intervention
Tadalafil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function
In Brief
A Phase 4 clinical trial evaluating Tadalafil and Placebo for Erectile Dysfunction. Completed, enrolled 623 participants across 40 sites in 2 countries.
Detailed Summary
The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartAug 2010
Primary CompletionJan 2012
TodayJul 2026
First PostedMay 26, 2010
Enrollment StartAug 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.1 years ago
Interventions
Tadalafildrug
Administer orally
Placebodrug
Administer orally